Efficacy of Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel versus Conventional Dose Doxorubicin, Cyclophosphamide Followed by Paclitaxel or Docetaxel in Patients with Node-Positive Breast Cancer

Yazılıtaş, Doğan; Şendur, Mehmet Ali Nahit; Karaca, Halıt; Özdemir, Nuriye; Aksoy, Sercan; Berk, Velı; Yazıcı, Ozan; Öztürk, Bayram; Özkan, Metin; Zengi̇n, Nurullah; Altundağ, Kadri̇

doi:10.7314/apjcp.2015.16.4.1471

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After that, NUSAP1 gradually became the focus in various tumor research. Brinkley found that spindle defects lead to genomic instability in invasive tumor cells with NUSAP1 loss [19]. Raemaekers found that NUSAP1 is localized in the nucleus and spindle and is over-expressed in proliferating cells in phase G2/M, resulting in spindle bundle bundling and inhibiting cell proliferation [18].…”

Section: Discussionmentioning

confidence: 99%

Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression

Zhang

Pan

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundDifferentially expressed genes (DEGs) of IBC were selected from the Gene Expression Omnibus (GEO) chip data: GSE21422 and GSE21974. Network analysis of the DEGs and IBC-related genes was performed in STRING database to find the core gene. Thus, this study aimed to determine the role of NUSAP1 in invasive breast cancer (IBC) and to investigate its effect on drug susceptibility to epirubicin (E-ADM).Material/MethodsThe mRNA expression of NUSAP1 was determined by quantitative polymerase chain reaction (q-PCR). The protein expression was detected by Western blotting. Cell growth and growth cycle were detected by MTT assay and flow cytometry, respectively. Cell migration and invasion were tested by Transwell assay.ResultsThrough use of gene network analysis, we found that NUSAP1 interacts with IBC-related genes. NUSAP1 presented high expression in IBC tissue samples and MCF-7 cells. NUSAP1 overexpression promoted the growth, migration, and invasion of MCF-7 cells. While NUSAP1 gene silencing downregulated the expression of genes associated with cell cycle progression in G2/M phase, cyclin D kinase (CDK1) and DLGAP5 arrested cells in G2/M phase and significantly inhibited the growth, migration, and invasion of MCF-7 cells. si-NUSAP1 increased the susceptibility of MCF-7 cells to E-ADM-induced apoptosis.ConclusionsOur study provides evidence that downregulation of NUSAP1 can inhibit the proliferation, migration, and invasion of IBC cells by regulating CDK1 and DLGAP5 expression and enhances the drug susceptibility to E-ADM.

show abstract

Section: Discussionmentioning

confidence: 99%

Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression

Zhang

Pan

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…The incidence of severe peripheral neuropathy in our patients was relatively higher (4 vs. 27) than reported in other randomized controlled trials. 38,39 During the treatment with AC regimen and AC part of the AC-T regimen, our study participants reported only mild peripheral neuropathy compared to randomized controlled trials. 40 Hence, the cumulative dose of AC chemotherapy might increase the risks of paclitaxelinduced severe peripheral neuropathy later.…”

Section: Discussionmentioning

confidence: 85%

Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study

Alemayehu

Assefa

Wang

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background: Management of patients with breast cancer undergoing chemotherapy is complicated by a very high rate of adverse drug reactions which is even more challenging in developing countries like Ethiopia where the toxicity profile of chemotherapy is lacking. The present study aimed at evaluating the toxicity profile of Doxorubicin-Cyclophosphamide (AC) and Doxorubicin-Cyclophosphamide!Paclitaxel (AC!T) regimens among 146 patients with breast cancer in Ethiopia. Methods: This prospective cohort study, with the median of six months' follow-up, was conducted from January 1 to September 30, 2017 GC at the only nationwide oncology center, Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia. Seventy-one patients received AC, while 75 received ACT regimen. The toxicity with the highest grade during any cycle was considered as the toxicity grade for that patient. SPSS version 22 was used for analysis. Results: The overall frequent non-hematological adverse drug reactions reported for both regimens were fatigue 144 (98.7%), dysgeusia 142 (97.3%), skin hyperpigmentation 141 (96.6%), nausea 136 (93.2%), vomiting 129 (88.4%), gastritis 122 (83.6%), peripheral neuropathy 108 (74%), and myalgia/arthralgia 110 (75.3%). Neutropenia 107 (73.3%), leukopenia 102 (69.9%), and anemia 51 (34.9%) were the most frequent overall grade hematological toxicities reported. However, those received AC regimen suffered more from grade 2 and above leukopenia (35.2% vs. 17.3%, P ¼ 0.014), anemia (16.9% vs. 2.7%, P ¼ 0.004), and alkaline phosphatase increment (11.3% vs. 2.7%, P ¼ 0.039) than ACT regimen. On the contrary, those received ACT regimen suffered more from severe arthralgia/myalgia (2.8% vs. 2%, P ¼ 0.001), peripheral neuropathy (1.4% vs. 36%, P ¼ 0.000), and gastritis (14.1% vs. 29.3%, P ¼ 0.026) than AC regimen. Pretreatment blood cell counts, having stage IV breast tumor, older age, and lower body surface area were significant predictors of grade 2 to above hematological toxicities. Older age, arthralgia/myalgia, and skin hyperpigmentation occurred during the cohort were significant predictors of grade 2 to above oral mucositis, peripheral neuropathy, and fatigue, respectively. Conclusion: Patients who received the AC regimen suffered more from hematological abnormalities, while those on the ACT regimen experienced more of non-hematological toxicities. Overall, we report high incidences of AC and ACT regimens-induced toxicities in Ethiopian women with breast cancer, and they may require prior support based on pretreatment blood counts, age and body surface area, and close follow-up during chemotherapy.

show abstract

“…Breast cancer is the most frequently diagnosed cancers and the leading causes of cancer death in women , and approximately one-third of breast cancer cases are expected to occur in women <50 years of age (Siegel et al, 2015). Chemotherapy has been the mainstay of adjuvant therapy for premenopausal women with node-positive breast cancer, and its effect was much higher in younger women than in older women (Yazilitas et al, 2015). The benefit of adjuvant chemotherapy has been supposed that at least part of it is derived from chemotherapyinduced ovarian ablation.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Chemotherapy-Induced Amenorrhea in Breast Cancer: a Meta-Analysis

Zha

Tang²,

Li³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: There is still a great deal of controversy with regard to the prognostic role of chemotherapyinduced amenorrhea (CIA) in breast cancer patients. To confirm whether CIA can serve as a useful factor in predicting clinical effects of systemic adjuvant chemotherapy, we performed this meta-analysis. Materials and Methods: Relevant studies were identified using PubMed, and Embase databases. Eligible study results were pooled and summary hazard ratios (HRs) with corresponding confidence intervals (CIs) were calculated. Subgroup analyses and an assessment of publication bias were also conducted. Results: A total of 8,333 patients from 11 published studies were identified through searching the databases. The pooled HRs for disease-free survival (DFS) suggested that CIA was associated with a significant reduction in the risk of recurrence, especially in patients with hormone receptor-positive lesions (overall HR=0.65, 95%CI 0.53-0.80, I 2 = 41.3%). When the five studies reporting the HR for overall survival (OS) were pooled (n=4193), a favorable trend was found (HR=0.69, 95%CI 0.52-0.91, I 2 = 51.6%). No publication bias was observed in this study. Conclusions: This meta-analysis suggests that CIA predicts a better outcome in premenopausal hormone receptor-positive breast cancer patients.

show abstract

Efficacy of Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel versus Conventional Dose Doxorubicin, Cyclophosphamide Followed by Paclitaxel or Docetaxel in Patients with Node-Positive Breast Cancer

Cited by 3 publications

References 30 publications

Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression

Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression

Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study

Prognostic Value of Chemotherapy-Induced Amenorrhea in Breast Cancer: a Meta-Analysis

Contact Info

Product

Resources

About